Visit Us
2008 AACC Clinical Lab Expo
July 29 - 31, 2008
Washington, DC
Trinity Biotech Booth
Products
Newborn Screening Assay
Primus is pleased to introduce its Neonatal Screen, a new HPLC assay for detecting hemoglobin variants in newborns. Identifies F, A, and clinically significant variants S, C, D, E, O, and Bart's plus many more with the largest variant library available. The superior separation technology that has distinguished Primus for adult hemoglobin variant testing has been adapted to newborn screening to provide quality presumptive hemoglobin identifications. The FDA cleared system incorporates a 2 minute screening method with an automatic transition to a confirmatory method without user intervention that is unique to Primus. It is completely automated from sample dilution to transmission of phenotypes to the LIS. Windows XP® provides functionality along with ease of use. Call today for more information at (800)377-4752 or e-mail us at sales@primusdiagnostics.com.
Press Releases
FOR IMMEDIATE RELEASE
July 29, 2005
TRINITY BIOTECH COMPLETES ACQUISITON OF
PRIMUS CORPORATION
Kansas City, MO… Primus Corporation is pleased to announce our new affiliation with Trinity Biotech, Bray, Ireland. Trinity is a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets worldwide.
Primus' existing customer and distributor contracts
will not change due to this new association. Trinity has a broad distribution base and technical support infrastructure that will provide more opportunities for expansion of our sales and service network. The union of the two companies will enhance Primus' ability to support our customers more effectively and efficiently.
Thank you for your continued support and loyalty, and be assured that it is "business as usual" here at Primus. F
or additional product information, please visit our website at www.primusdiagnostics.com.
Tom Reidy
President
Primus Corporation
# # #
Global Compliance
Primus Corporation is a registered FDA Medical Device Manufacturer who maintains a Quality System that is compliant with FDA Quality System Regulation (21 CFR Part 820) and the ISO 13485 Quality System. Our team has extensive experience in design that incorporates the ISO 14971 Medical Device Risk Management guidelines, including UL and CSA. We have completed our CE Mark certification (Directive 98/79/EEC) and FDA Certificate to Foreign Governments for global distribution and sale of reagents, columns, liquid control material and instruments.
Primus maintains Design History Files, document and design control on all platforms. We have expertise in software control and validation. All Primus medical device platforms are designed according to the latest global compliance standards (21 CFR 11 and FDA-CDRH General Principles of Software Validation).
Continued Commitment To Quality
The goal at Primus is to design and engineer products of superior quality using the best materials available in the production of those products, and we are meeting our goal.
Our team members are trained and equipped to build into and promote quality in all areas…a critical component in our ongoing commitment to excellence. Quality management systems are developed and employed to ensure that all products and services meet the global standards set for them.
Quality, innovation, excellence…the Primus way.
 |
|
|
|
 |
|
||
 |
 |
 |
|
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
 |
||
 |
|
||
 |
|
||
 |
|
||